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FOOTNOTES TO THE TEXT 
 
1The abbreviations used are: PLA2, phospholipase A2; cPLA2, cytosolic PLA2; iPLA2, 
Ca2+-independent PLA2; sPLA2, secreted PLA2; AA, arachidonic acid;  BEL, 
bromoenol lactone; MAFP, methyl arachidonyl fluorophosphonate; lysoPC, 
lysophosphatidylcholine. 
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ABSTRACT 
Group VIA calcium-independent phospholipase A2 (iPLA2) has been shown to play a 
major role in regulating basal phospholipid deacylation reactions in certain cell types. 
More recently, roles for this enzyme have also been suggested in the destruction of 
membrane phospholipid during apoptosis, and after oxidant injury. Proposed iPLA2 
roles have rested heavily on the use of bromoenol lactone as a selective iPLA2 
inhibitor, but this compound actually inhibits other enzymes and lipid pathways 
unrelated to PLA2, which  makes it difficult to define the contribution of iPLA2 to 
specific functions. In previous work we pioneered the use of antisense technology to 
decrease cellular iPLA2 activity as an alternative approach to study iPLA2 functions. 
In the present study we have followed the opposite strategy and have prepared U937 
cells that exhibit enhanced iPLA2 activity by stably expressing a plasmid containing 
iPLA2 cDNA. Compared with control cells, the iPLA2-overexpressing U937 cells show 
elevated responses to hydrogen peroxide with regard to both arachidonic acid 
mobilization and incorporation of the fatty acid into phospholipids, thus providing  
additional evidence for the key role that iPLA2 plays in these events. Long-term 
exposure of the cells to hydrogen peroxide results in cell death by apoptosis, and this 
process is accelerated in the iPLA2-overexpressing cells. Increased phospholipid 
hydrolysis and fatty acid release also occur in these cells. Unexpectedly however, 
abrogation of U937 cell iPLA2 activity by either methyl arachidonyl fluorophosphonate 
or an antisense oligonucleotide does not delay or decrease the extent of apoptosis 
induced by hydrogen peroxide. These results indicate that although iPLA2-mediated 
phospholipid hydrolysis occurs during apoptosis, iPLA2 may actually be dispensable 
for the apoptotic process to occur. Thus, beyond a mere destructive role, iPLA2 may 
be playing other roles during apoptosis.  
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Phospholipase A2s (PLA2)1 constitute a diverse group of enzymes whose common 
feature is to hydrolyze the fatty acid at the sn-2 position of phospholipids. Several 
mammalian intracellular and extracellular PLA2s have been characterized in recent 
years and classified into fourteen group types on the basis of sequence data [1, 2]. 
Attending to their biochemical characteristics, the PLA2s are generally grouped into 
three major subfamilies, namely secreted PLA2s (sPLA2), cytosolic Ca2+-dependent 
PLA2 (cPLA2), and cytosolic Ca2+-independent PLA2 (iPLA2) [1-6]. sPLA2s are 
extracellular, low molecular mass enzymes that require millimolar Ca2+ 
concentrations for activity. cPLA2, specifically the α isoform, is an intracellular 
enzyme that plays a pivotal role in receptor-coupled arachidonic acid (AA) release 
and prostaglandin production. Whereas cPLA2α has a striking selectivity for AA-
containing phospholipids, sPLA2s do not exhibit acyl chain specificity.  
iPLA2s are Ca2+-independent cytosolic enzymes whose functional role(s) in 
cells has recently gained interest [7, 8]. Among the iPLA2s, the better studied is the 
one classified as Group VIA. This is an 85-kDa enzyme that shows no fatty acid 
selectivity and is potently and irreversibly inhibited by bromoenol lactone (BEL) [7, 8]. 
Evidence suggests that Group VIA iPLA2 is directly involved in maintaining the 
homeostatic levels of lysophosphatidylcholine (lysoPC) in resting cells [9]. Since 
lysoPC is the main acceptor of free AA for its incorporation into phospholipid pools 
[10], Group VIA iPLA2 has been implicated in phospholipid fatty acyl chain 
deacylation/reacylation reactions (i.e. the Lands cycle). In these reactions, a 
phospholipid containing a saturated fatty acid in the sn-2 position is cleaved by 
Group VIA iPLA2, and the resulting lysophospholipid acceptor is acylated by CoA-
dependent acyl transferases with a polyunsaturated fatty acid such as AA. This 
proposal, based on the demonstration that inhibition of cellular iPLA2 by BEL or a 
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specific antisense oligonucleotide blocks AA incorporation, was originally described 
in P388D1 macrophages [11, 12] and later confirmed by others in a number of 
mammalian cells [13-15].  
It seems likely however, that neither Group VIA iPLA2 is the only enzyme 
involved in maintaining homeostatic lysophospholipid levels [16] nor is that the only 
cellular function of Group VIA iPLA2 in cells. Recent evidence has implicated this 
enzyme in the destruction of membrane phospholipid subsequent to the cells 
entering apoptosis, resulting in the liberation of various free fatty acids to the 
extracellular medium [17-19]. Another instance wherein iPLA2-mediated 
phospholipolysis occurs in a seemingly receptor-uncontrolled manner is during 
oxidative stress [20, 21]. Finally, cells from schizophrenic patients have been 
reported to exhibit a constitutively elevated phospholipid fatty acid turnover, which 
appears to be mediated by an iPLA2-like activity [22].  
To further expand our investigations on cellular functions of Group VIA iPLA2 
in human U937 cells [9, 16, 20, 23, 24], we have prepared stably transfected cells 
that overexpress Group VIA iPLA2. Utilizing this strategy, we have re-assessed the 
role of iPLA2 in oxidant-induced AA release and incorporation into phospholipids, and 
extended our studies to the role of iPLA2 in oxidant-induced apoptosis.  
 
 
 
EXPERIMENTAL PROCEDURES 
 
 Materials. [5,6,8,9,11,12,14,15-3H]AA (200 Ci/mmol) and [3H]choline chloride 
(80 Ci/mmol) were purchased from Amersham Ibérica (Madrid, Spain). BEL and the 
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Group VIA iPLA2 antibody were from Cayman (Ann Arbor, MI). pcDNA3.1 vector 
containing the mouse Group VIA iPLA2 gene was kindly provided by Dr. Suzanne 
Jackowski (St. Jude Children’s Research Hospital, Memphis, TN) [25]. All other 
reagents were from Sigma (St. Louis, MO). 
Cell culture. U937 cells were maintained in RPMI 1640 medium supplemented 
with 10% (v/v) fetal calf serum, 2 mM glutamine, penicillin (100 units/ml) and 
streptomycin 100 µg/ml. For experiments, the cells were incubated at 37°C in a 
humidified atmosphere of CO2/O2 (1:19) at a cell density of 0.5-1 x 106 cells/ml in 12-
well plastic culture dishes (Costar). Differentiation was achieved by treating the cells 
with 35 ng/ml PMA for 24 h. 
  Production of transfectants stably expressing Group VIA iPLA2.  The plasmid 
containing Group VIA iPLA2 (approx. 2 µg per 106 cells) was transfected by 
electroporation at 270 V (975 µF) using a Gene Pulser II electroporator (Bio-Rad). To 
select for the transfected cells, they were incubated in medium containing 1 mg/ml 
geneticin. To obtain the transfectants stably expressing Group VIA iPLA2, the 
transfected cells were cloned by limiting dilution in medium containing 300 µg/ml 
geneticin.  After two weeks, wells containing a single colony were chosen for further 
expansion and the iPLA2 expression was analyzed by immunoblot and measurement 
of iPLA2 activity. The clones were always grown in medium containing  300 µg/ml 
geneticin.  
 Immunoblot analyses. Cells were lysed in an ice-cold lysis buffer, and 15 µg of 
cellular protein from each sample were separated by standard 10% SDS-PAGE and 
transferred to nitrocellulose membranes. Dilution of both primary and secondary 
antibodies was made in phosphate-buffered saline containing 0.5% defatted dry milk 
and 0.1% Tween 20. After 1 h incubation with primary antibody at 1:1000, blots were 
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washed 3 times and an anti-rabbit secondary peroxidase-conjugated antibody was 
added for another h. Immunoblots were developed using the Amersham ECL system. 
 iPLA2 assay – Briefly, aliquots of U937 cell homogenates were incubated for 2 
h at 37°C in 100 mM Hepes (pH 7.5) containing 5 mM EDTA and 100 µM labeled 
phospholipid substrate (1-palmitoyl-2-[3H]palmitoyl-glycero-3-phosphocholine, sp. 
act. 60 Ci/mmol, American Radiolabeled Chemicals, St. Louis, MO) in a final volume 
of 150 µl. The phospholipid substrate was used in the form of sonicated vesicles in 
buffer. The reactions were quenched by adding 3.75 volumes of chloroform/methanol 
(1:2). After lipid extraction, free [3H]palmitic acid was separated by thin-layer 
chromatography.  
 Measurement of lysoPC. Cells labeled with 0.5 µCi/ml [3H]choline for 2 days 
were used. After the incubations, lipids were extracted with ice-cold n-butanol and 
separated by thin-layer chromatography with chloroform/methanol/acetic acid/water 
(50:40:6:0.6) as a solvent system. Spots corresponding to lysoPC were scraped into 
scintillation vials and the amount of radioactivity was estimated by liquid scintillation 
counting. 
Measurement of [3H]AA release, and of [3H]AA incorporation into 
phospholipids. For the AA release experiments, the cells were labeled with 0.5 µCi/ml 
[3H]AA for 18 h. Under these conditions, equilibrium labeling of AA pools with  [3H]AA 
is reached. After this period, the cells were washed and placed in serum-free medium 
for 1 h before the addition of the appropriate stimulus in the presence of 0.5 mg/ml 
bovine serum albumin. The supernatants were removed, cleared of cells by 
centrifugation, and assayed for radioactivity by liquid scintillation counting.  
[3H]AA release under these equilibrium conditions represents a balance 
between what is liberated directly from phospholipids minus what is re-incorporated 
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back into phospholipids by the action of acyltransferases. [3H]AA incorporation into 
phospholipids cannot be measured simultaneously with [3H]AA release, because the 
former could not be distinguished from the endogenous phospholipid-bound [3H]AA 
that has not been mobilized by PLA2. To circumvent this problem, AA incorporation 
experiments were conducted in parallel under the same experimental conditions as 
those employed above for [3H]AA release, but unlabeled cells were used instead and 
exogenous [3H]AA was added together with the stimulus. Briefly, the cells were 
placed in serum-free medium for 1 h before exposure to exogenous [3H]AA (10 µM, 
0.5 µCi/ml) in the presence or absence of the indicated stimuli. At the indicated times, 
supernatants were removed and the cell monolayers were scraped twice with 0.1% 
Triton X-100. Total lipids were extracted and were separated by thin-layer 
chromatography with n-hexane/diethyl ether/acetic acid (70:30:1 by volume). Spots 
corresponding to phospholipid were scraped and their radioactive content was 
determined by scintillation counting. 
Antisense oligonucleotide treatments. The iPLA2 antisense oligonucleotide 
utilized in this study has been described in previous studies from our laboratory  [12, 
20, 23, 24]. The iPLA2 antisense sequence corresponds to nucleotides 59-78 in the 
murine group VIA iPLA2 sequence, which is conserved in human group VIA iPLA2 
[26, 27]. The antisense or sense oligonucleotides were mixed with lipofectamine, and 
complexes were allowed to form at room temperature for 10-15 min. The complexes 
were then added to the cells, and the incubations were allowed to proceed under 
standard cell culture conditions. The final concentrations of oligonucleotide and 
lipofectamine were 1 µM and 10 µg/ml, respectively. Oligonucleotide treatment and 
culture conditions were not toxic for the cells as assessed by the Trypan blue dye 
exclusion assay and by quantitating adherent cell protein. 
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Conditions for the use of a human cPLA2 antisense oligonucleotide were taken 
from Tomassini and Cantoni [28]. The oligonucleotides used were: antisense: 5’-TAC 
AGT AAA TAT CTA GGA ATG-3’; and sense (random sequence of the antisense 
bases): 5’-CCT ACT GAG GGT ACG GTA CAT-3’). The oligonucleotides were 
phosphorothioate-modified (MWG Biotech, Ebersberg, Germany). The U937 cells 
were washed twice with serum-free medium and seeded at a cell density of 106 per 
ml in serum-free medium for 6 h in the absence of presence of the oligonucleotides 
(10 µM). A final concentration of 5% fetal bovine serum was added and the cells 
were cultured for an additional 48 h, and finally used for experiments. 
Measurement of apoptosis. Apoptosis was analyzed by labeling with the 
Annexin-V FITC Apoptosis Detection Kit (Pharmingen), that recognizes 
phosphatidylserine exposure on outer leaflet of the plasma membrane.  The cells 
were analyzed by flow cytometry using a Coulter-Epics XL-MCL cytofluorimeter. 
Data presentation. Assays were carried out in duplicate or triplicate. Each set 
of experiments was repeated at least three times with similar results. Unless 
otherwise indicated, the data presented are from representative experiments. 
 
 
 
RESULTS 
 
Characterization of U937 cells overexpressing Group VI iPLA2 - Transfection 
of U937 cells with a plasmid containing mouse Group VIA iPLA2 followed by selection 
of geneticin-resistant clones resulted in the isolation of a stably transfected clone 
expressing a 3-4-fold increase in iPLA2 activity as compared to control cells 
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transfected with an empty plasmid (Fig. 1A). The stably transfectants also showed 
increased levels of an 85 kDa protein that was recognized by the anti-iPLA2 antibody 
from Cayman (Fig. 1A, inset). In addition, the stably transfected cells also exhibited a 
2-3 increase in the steady-state level of cellular lysoPC, as measured in cells labeled 
with [3H]choline (Fig. 1B). Importantly, increased iPLA2 expression was not a 
permanent phenotype of the transfected cells, as it did not persist on serial passages 
in culture. Appreciable losses of both iPLA2 activity and immunoreactive protein were 
detected at approx. 20 cell passages. Interestingly, we have consistently failed to 
obtain expression --either transient or stable--, of an iPLA2 dominant negative mutant 
in which the catalytic Ser465 had been replaced by Ala. These data appear to suggest 
that large increases or decreases in the intracellular iPLA2 activity content are 
injurious for the U937 cells, which in turn highlight the importance that this class of 
enzymes may have in the regulation of homeostatic phospholipid metabolism. 
When exposed to H2O2, U937 macrophage-like cells have been shown to 
liberate fatty acids, including AA, in a process that appears to depend on iPLA2 [20]. 
Fig. 2 shows that the iPLA2-overexpressing cells liberated more AA than did control 
cells when exposed to H2O2. Basal release (i.e, that determined in the absence of 
H2O2) was also increased in the iPLA2-overexpressing cells. As a control for these 
experiments, the effect of concanavalin A on AA release from these cells was also 
investigated. Concanavalin A is known to signal to AA release in U937 cells by 
directly activating the cPLA2, and the iPLA2 is not involved [20]. In accordance with 
these previous findings, iPLA2 overexpression did not result in an increased AA 
release response of the cells to concanavalin A (data not shown). Thus, iPLA2 
overexpression does not impact on cellular functions that do not depend on iPLA2. To 
further strengthen the lack of involvement in H2O2-induced AA mobilization, 
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experiments were conducted in which cPLA2 expression was knocked out by 
antisense technology (Fig. 3). Only partial inhibition of cPLA2 could be achieved (38 ± 
5% inhibition as assessed by immunoblot, Fig. 3 inset), which was not unexpected, 
given the high levels of cPLA2 that the U937 cells are known to express [29, 30]. 
Despite such a low inhibition, we were still able to detect significant inhibition of the 
Con A-induced AA release (Fig. 3). Importantly, parallel measurement of the H2O2-
induced AA mobilization showed no detectable effect (Fig. 3). These data, along with 
our previous data showing no inhibition of the H2O2-induced AA release by the 
cPLA2-specific inhibitor pyrrophenone [20], strengthen the lack of a role for cPLA2 in 
oxidant-induced AA mobilization in U937 cells. 
 Role of iPLA2 in AA incorporation into U937 cell phospholipids exposed to 
H2O2 - Rather than reflecting enzyme activation per se, iPLA2-mediated fatty acid 
release in response to H2O2 is thought to occur because of a facilitated interaction of 
the enzyme with its substrate, secondary to H2O2-induced membrane oxidation [20]. 
However, previous studies by Sporn et al. [31] utilizing alveolar macrophages have 
suggested that a major route by which H2O2 induces AA mobilization in these cells is 
by impairing fatty acid esterification into phospholipid. Similar results have been 
reported by Cane et al. [32] in vascular smooth muscle cells. Since AA mobilization in 
response to stimuli represents a balance between what is released from 
phospholipids by phospholipases minus what is reincorporated back into 
phospholipids by acyltransferases, we explored whether in the U937 cells, H2O2 
induced AA release also involves inhibition of fatty acid incorporation into 
phospholipids.  
In the first series of experiments, we assayed H2O2-induced AA release in the 
presence of thimerosal, a well known inhibitor of fatty acyl-CoA synthetases and 
 12 
hence, of fatty acid incorporation into phospholipids [33, 34]. Figure 4 shows that 
thimerosal did not affect AA release on its own, but markedly augmented [3H]AA 
release in response to H2O2. This clearly suggests that the H2O2 effect on AA release 
did not involve an inhibitory effect on AA acylation into phospholipids. 
We directly assayed the effect of H2O2 on AA incorporation into phospholipids 
in the experiments depicted in Fig. 5. Treating the cells with H2O2 not only did not 
inhibit exogenous AA incorporation but actually enhanced it. Given our previous data 
showing that H2O2 increases iPLA2 activity in the U937 cells [20], this unexpected 
finding correlates well with the proposed role of iPLA2 as a major provider of the 
lysoPC acceptors utilized in the initial incorporation of AA into cellular phospholipids. 
Thus, the simplest explanation for the enhancing effect of H2O2 reported in Fig. 5 is 
that H2O2, by increasing iPLA2 activity, acts to elevate the intracellular pool of lysoPC 
and this increases AA incorporation. 
 Further proof to the above view was obtained when AA incorporation was 
studied in the iPLA2 stably transfectants which, as indicated above, present higher 
amounts of lysoPC to serve as the acyl acceptors. The iPLA2 overexpressing cells 
incorporated more exogenous AA into phospholipids than did control cells 
transfected with an empty vector (Fig. 6). Moreover, when the AA incorporation 
experiments were conducted in the presence of H2O2, additional increases were 
observed again in both the untrasfected and the iPLA2-overexpressing cells (Fig. 6). 
All these increases were significantly blunted by BEL (~40% inhibition), confirming 
the involvement of iPLA2 in the response (Fig. 7). It should be noted however, that 
the fact that BEL does not completely blunt AA incorporation indicates that there are 
other pathways in addition to iPLA2 that may significantly contribute to overall AA 
incorporation into cellular phospholipids [16]. Interestingly, pyrrophenone, a specific 
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cPLA2 inhibitor, failed to exert any significant effect on the response (not shown). 
Collectively, findings in Figs. 5-7 do support an important role for iPLA2 in AA 
incorporation into U937 cell phospholipids.  
Role of iPLA2 in H2O2-induced apoptosis - H2O2 is known to induce apoptosis 
in a number of cells [35, 36], and there is evidence that unesterified fatty acids such 
as AA inside the cells can signal apoptosis [37]. Since iPLA2 is responsible for 
liberating fatty acids in response to H2O2, the possibility arises that iPLA2 may be a 
key signaler of H2O2-induced apoptosis. Figure 8 shows that almost 40% of the U937 
cells exposed to 500 µM H2O2 underwent apoptosis at 20 h, as measured by the 
annexin-V-FITC assay. Importantly, the fraction of cells undergoing apoptosis was 
doubled if iPLA2 overexpressing cells were used (Fig. 8). As a control for these 
experiments we used BEL, which is known to induce apoptosis in U937 cells in an 
iPLA2-independent manner [24]. More than 90% of the cell population underwent 
apoptosis in the presence of BEL and this happened in both control and iPLA2-
overexpressing U937 cells (Fig. 8). Fig. 9A shows that in [3H]AA-labeled cells, the 
iPLA2 transfectants exhibited larger losses of cellular phospholipid content than did 
control cells exposed to H2O2. These phospholipid losses correlated with higher 
levels of [3H]AA in the incubation media, as compared to parental cells (Fig. 8B). 
Thin-layer chromatographic analyses of the radioactivity accumulating in the 
extracellular medium revealed that more than 80% of it corresponded to free fatty 
acid. Collectively, data in Figs. 8 and 9 suggest that iPLA2 participates in H2O2-
induced apoptosis of U937 cells, and promotes destruction of membrane 
phospholipid . 
The effect of iPLA2 inhibition on H2O2 apoptosis was assayed next. The cells 
were incubated with MAFP, a dual cPLA2/iPLA2 inhibitor that, unlike BEL, does not 
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induce apoptosis of the U937 cells on its own [24]. Preliminary experiments carried 
out with the specific cPLA2 inhibitor pyrrophenone had shown no effect of this 
compound on H2O2-induced apoptosis, which rules out a role for cPLA2 in the 
process, in agreement with previous reports [17, 18]. Unexpectedly, incubating the 
cells for 6, 8 or 20 h with 10-25 µM MAFP ---concentrations which we have 
previously shown to completely inhibit cellular iPLA2 activity [24]-- also failed to 
decrease the extent of H2O2-induced apoptosis, as measured by the annexin V-FITC 
surface binding assay (Fig. 10A). In agreement with these data, U937 cells made 
deficient in iPLA2 by antisense treatment exhibited no decreased apoptosis in 
response to H2O2 (Fig. 10B). These results suggest that, although iPLA2-mediated 
phospholipid breakdown does occur during H2O2-induced apoptosis, the apoptotic 
process itself still can occur in the absence of iPLA2.  
 
 
 
 
DISCUSSION 
 
H2O2 is an oxidant generated in large quantities by phagocyte cells by the 
action of superoxide dismutase on superoxide anion. Excessive accumulation of 
H2O2 is known to cause lipid peroxidation, which may compromise cellular function 
and, ultimately leading to cytotoxicity.  
H2O2 is widely used as an oxidant stressor for the study of oxidation-induced 
signaling events in different cell models. In previous work, we have described the 
molecular mechanism for fatty acid mobilization during H2O2-induced oxidative 
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damage in U937 cells and found an unexpected role for Group VIA iPLA2 as a main 
participant in the process [20]. Probably by increasing the amount of lipid peroxides 
at the membrane, the oxidant was found to increase the accessibility/susceptibility of 
iPLA2 towards its substrate, which resulted in increased fatty acid release [20]. From 
a biochemical viewpoint this iPLA2 role is striking since, under true activation 
conditions --i.e. those involving the activation of receptor-dependent or -independent 
intracellular signaling cascades--, there is general recognition that cPLA2α, not iPLA2, 
is an absolute requirement for AA mobilization in phagocyte cells. While inhibition of 
cPLA2α strongly blunts receptor-induced AA mobilization in phagocytes, inhibition of  
iPLA2 by BEL does not generally affect the response [20, 38-42]. 
iPLA2 involvement in oxidant-induced phospholipid hydrolysis has also been 
recognized to occur in uterine stromal cells [21] and, more recently, in astrocytes as 
well [43]. Interestingly however, in cells such as alveolar macrophages [31] and 
vascular smooth muscle cells [32], oxidant-induced AA mobilization was found to 
result from impairment of fatty acid incorporation into phospholipids. Given the key 
role that iPLA2 appears to play in AA deacylation/reacylation reactions in 
immunoinflammatory cells [7, 8], it was of interest to assess the effect of H2O2 on the 
AA incorporation mechanisms of U937 macrophage-like cells. Initial studies were 
carried out with thimerosal, an organometalic compound that blocks AA reacylation 
but spares deacylation via PLA2 [33, 34]. This compound markedly enhanced the 
H2O2-induced AA mobilization, a finding that is consistent with the H2O2 effect being 
on the phospholipolytic step and not on the reacylation step. Thus, if an inhibitory 
effect of H2O2 on AA reacylation was the cause of the AA release, one would expect 
an additive or less-than-additive effect of thimerosal on the H2O2 response, as 
demonstrated in the studies by Sporn et al. [31] and Cane et al. [32]. On the contrary, 
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if a stimulatory effect  of H2O2 on the PLA2-mediated deacylation step was the cause 
of the AA release, then the effects of H2O2 plus thimerosal should be supra-additive 
or synergistic. This is  exactly what we observed in the experiments  described in this 
report. 
Analyses of the effect of H2O2 on the AA incorporation capacity of the cells 
indicate that the oxidant not only does not block AA esterification into phospholipids, 
but actually enhances it. Thus, despite the oxidant increasing fatty acid esterification 
into phospholipids, the net result is an increase in fatty acid mobilization, which 
indicates that the effect of H2O2 on the iPLA2 is stronger and thus prevails.  
Taking into account that H2O2 does not affect either positively or negatively the 
activities of the AA reacylating enzymes arachidonoyl-CoA synthetase or the 
arachidonoyl-CoA acyltransferase [31], a plausible explanation for the phenomena 
herein described is that accelerated hydrolysis of phospholipids by iPLA2 in the 
presence of H2O2 leads to accumulation of intracellular lysophospholipid acceptors, 
which in turn triggers feed-back increase of AA incorporation into phospholipids.  
Thus, the biochemical significance of the AA incorporation data in the H2O2-treated 
cells is that not all of the AA released from phospholipids by iPLA2 will be available 
for further metabolism. Rather, a significant portion of free AA will be incorporated 
back into phospholipids, limiting in this way the amount of free AA available for 
further metabolic reactions. 
Control of the intracellular level of lysophospholipid acceptors utilized for 
incorporation of AA into phospholipids is one of the earliest proposed roles for iPLA2 
in phagocyte cells. This role was demonstrated by studies in which iPLA2 activity was 
reduced in cells by either pharmacological or antisense inhibition approaches [7, 8, 
11, 12].  In the current study we have employed a third different approach, which is 
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the opposite of the other two previously employed. We have prepared cells that 
stably overexpress iPLA2 to confirm previous functional roles proposed for the 
enzyme, and to study new ones. As would be expected from the model discussed 
above, the iPLA2 overexpressing cells exhibit a significantly higher capacity to 
incorporate AA into phospholipids than control cells. Also, the iPLA2 overexpressing 
cells mobilize larger quantities of free AA in response to H2O2. Thus, these results 
provide new evidence for the key role of iPLA2 in mediating phospholipid hydrolysis 
during oxidative stress by H2O2. In turn, the results provide additional evidence for 
the key role of iPLA2 in regulating the intracellular levels of lysoPC to be used for fatty 
acid incorporation via the Lands cycle.   
Studies on whether lysoPC levels limit the initial rate of AA incorporation into 
phospholipids in cells not of the phagocytic lineage have also recently been carried 
out. In pancreatic islet cells, the steady-state levels of lysoPC appear to be so high 
that even after acute inhibition of endogenous iPLA2, the cells still retain at least 80% 
of their initial lysoPC content [44]. Thus the initial rate of AA incorporation into islet 
phospholipids is not altered, suggesting that in these cells the iPLA2 is not required 
for the initial AA incorporation into phospholipids. Nevertheless, it should be noted 
that islet iPLA2 is estimated to provide at least 20% of the very high lysoPC levels 
that these cells contain [44], which suggests that the enzyme still possesses 
significant housekeeping activity with regard to the maintenance of endogenous 
lysoPC levels.  
Transient overexpression of iPLA2 into COS cells has been found to 
significantly increase lysoPC levels without a concomitant increase in the 
incorporation of exogenous AA into phospholipids, suggesting that under these 
settings, lysoPC levels do not limit the initial rate of AA incorporation into 
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phospholipids [25]. Since the results obtained in COS cells were performed in 
transiently transfected cells, it is possible that acute alterations in phospholipid 
metabolism induced by transient overexpression of iPLA2 may not trigger normal 
physiological responses, as discussed elsewhere [45]. It is also possible that COS 
cells have a very limited capacity to incorporate AA into membrane phospholipids, 
and that the steady-state level of lysoPC in untrasfected cells is already high enough 
to account for a normal rate of incorporation of AA into the phospholipids of these 
cells. Thus, the excess amount of lysophospholipid produced by the iPLA2 
overexpressing cells would not be needed for AA incorporation. 
Our results in phagocytic cells, together with those in COS [25] and pancreatic 
islet cells [44, 46], appear to suggest that the mechanisms for lysophospholipid 
generation and the PLA2s involved in phospholipid fatty acyl chain remodeling may 
be cell-type specific. However, the results are also compatible with the hypothesis 
that a certain threshold level of intracellular lysophospholipid is necessary to support 
AA incorporation into phospholipids. In cells with a limited capacity of AA 
incorporation or in those with an exceedingly high steady-state lysophospholipid 
level, increasing and/or partially decreasing the intracellular level of lysoPC --by 
either iPLA2 overexpression [25, 46] or pharmacological inhibition [44], respectively-- 
may have little or no effect on the initial rate of AA incorporation. Conversely, in cells 
specialized in AA metabolism such as phagocytes, decreasing [11, 12] or increasing 
(this work) the intracellular level of lysoPC may lead to significant changes in the 
initial rate of AA incorporation. Thus lysoPC-dependent regulation of AA 
incorporation into phospholipids may be strikingly  characteristic of some cell types 
but not of others, and other factor(s) in addition to lysophospholipid availability may 
limit AA incorporation in certain cell types. 
 19 
Beyond the housekeeping role of iPLA2 in phospholipid fatty acid 
reacylation/deacylation reactions and in non-specific fatty acid release during oxidant 
injury discussed above, a role for iPLA2 in apoptosis has been suggested by the 
finding that apoptosis induction by either anti-Fas antibody or tumor necrosis factor 
plus cycloheximide in U937 cells is associated with iPLA2-mediated hydrolysis of 
membrane phospholipids [17, 18]. We have observed in this work that the extent of 
H2O2-induced apoptosis in U937 cells is higher if iPLA2-overexpressing cells are 
used. Increased destruction of membrane phospholipid and concomitant release of 
fatty acid to the supernatant were also observed under these conditions, confirming 
that iPLA2-mediated phospholipid hydrolysis does occur during apoptosis.  
Importantly however, treating the cells with an iPLA2 antisense 
oligonucleotide, or with MAFP under conditions that result in total inhibition of cellular 
iPLA2, does not prevent the H2O2-induced apoptosis. This suggests that iPLA2 
activity is, in the strict sense, not necessary for the apoptosis to take place. In 
support of this view, BEL induces apoptosis in a variety of cells via a caspase-3-
mediated pathway that necessarily proceeds in the absence of functional iPLA2 
activity [24; see also Fig. 8], and Atsumi et al. [18] have also noted that MAFP 
treatment of U937 cells does not prevent apoptosis in response to both anti-Fas 
antibody or tumor necrosis factor plus cycloheximide, although in this case, the drug 
was found to partially decrease apoptosis at early time periods. More recently,  
Lauber et al. [19] have reported that apoptosis of caspase-3-transfected MCF7 cells 
exposed to UV is not prevented by arachidonyl trifluoromethyl ketone. Although the 
latter result was taken by the authors to rule out a role for cPLA2 in apoptosis [19], 
arachidonyl trifluoromethyl ketone is also known to strongly inhibit iPLA2 [47, 48], 
which makes it likely that UV-induced apoptosis of caspase-3-transfected MCF7 cells 
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is also independent of iPLA2 [19].  
Collectively, all of the aforementioned examples suggest that, even though 
iPLA2 may participate in the early phase of apoptosis under certain conditions, the 
enzyme may actually be dispensable for the apoptotic process to fully develop. It is 
therefore conceivable that, beyond a mere destructive role, iPLA2-mediated 
phospholipid hydrolysis during oxidant injury may serve to provide those accessory 
signals –e.g. eat me, or attraction signals— that are triggered along with the 
destructive process itself [49, 50]. Thus, products of iPLA2 hydrolysis of cellular 
phospholipids during apoptosis, namely free fatty acids or perhaps lysophospholipids 
such as lysoPC [19, 51], might be involved in providing these signals. Experiments 
are currently under way to test this possibility during oxidant-induced apoptosis. 
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FIGURE CAPTIONS 
 
Figure 1. Overexpression of iPLA2 in U937 cells. A) The stably transfected cells 
(referred to as iPLA2 in the abscissa) were prepared as described under 
“Experimental Procedures”, and the levels of iPLA2 activity and immunoreactive 
protein were compared to those of parental cells transfected with an empty vector 
(pcDNA3.1). B) The cells were labeled with [3H]choline, and the level of radioactivity 
in lysoPC in the stably transfected cells (iPLA2) and control cells transfected with an 
empty vector (pcDNA3.1) was measured as described under “Experimental 
Procedures”. 
 
Figure 2. Effect of H2O2 on AA release from iPLA2-overexpressing (iPLA2) and control 
(pcDNA3.1) cells. AA release was measured at 1 h in cells exposed (closed bars) or 
not (open bars) to 500 µM H2O2. 
 
Figure 3. Effect of a cPLA2 antisense oligonucleotide on stimulus-induced AA 
release. The cells were treated with a sense oligonucleotide (gray bars), antisense 
oligonucleotide (black bars) or neither (open bars) as described under Experimental 
Procedures. Afterwards the cells were exposed to 500 H2O2, 100 µg/ml Con A or 
neither (Control) for 1 h, and AA release was determined. Inset shows the cPLA2 
protein content of control (C), sense-treated (S) or antisense-treated (A) cells, as 
measured by immunoblot. 
 
Figure 4. Effect of thimerosal on H2O2-induced AA release. The cells were either 
untreated (open symbols) or treated (closed symbols) with 500 µM H2O2 for 1 h in the 
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presence of the indicated concentrations of thimerosal. 
 
Figure 5. Effect of H2O2 on AA incorporation into U937 cell phospholipids. The cells 
were treated with exogenous [3H]AA for the indicated amounts of time in the absence 
(open symbols) or presence (closed symbols) of 500 µM H2O2, and AA incorporation 
into cellular phospholipids was measured as described under “Experimental 
Procedures”. 
 
Figure 6. Effect of H2O2 on AA incorporation into phospholipids in iPLA2-
overexpressing (iPLA2) and control (pcDNA3.1) cells. [3H]AA incorporation was 
measured at 1 h in cells exposed (closed bars) or not (open bars) to 500 µM H2O2, as 
described under “Experimental Procedures”. 
 
Figure 7. Effect of BEL on the incorporation of AA into phospholipids in iPLA2-
overexpressing (iPLA2) and control (pcDNA3.1) cells. [3H]AA incorporation was 
measured at 1 h in cells treated (cross-hatched bars) or not (open bars) with 25 µM 
BEL and in the absence (Ctrl) or presence of 500 µM H2O2. 
 
Figure 8. Annexin V-FITC labeling of iPLA2-overexpressing (iPLA2) and control 
(pcDNA3.1) cells. The cells were treated with 500 µM H2O2 (upper panels) or 25 µM 
BEL (lower panels) for 20 h in serum-free media, and stained with annexin V-FITC as 
described under “Experimental Procedures”. Labeling obtained after H2O2 or BEL 
treatment (open traces) is compared with that of cells treated with vehicle alone 
(gray-filled traces). 
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Figure 9. Changes of 3H-radioactivity in phospholipids (A) and extracellular fatty acid 
release (B) in [3H]AA-labeled U937 cells exposed to H2O2. The iPLA2-overexpressing 
(cross-hatched bars) or control (open bars) cells were exposed to H2O2 for the 
indicated amounts of time. Afterward, radioactivity in phospholipids and in the 
extracellular medium was quantified as described under “Experimental Procedures”. 
 
Figure 10. Role of iPLA2 in H2O2-induced apoptosis. A, The cells were treated without 
(open bars) or with (hatched bars) 25 µM MAFP, and then incubated with 500 µM 
H2O2 for the indicated times. After the incubations, the cells were stained with 
annexin V-FITC as described under “Experimental Procedures” and the number of 
apoptotic cells was determined by cytometry. Apoptosis in cells not treated with H2O2 
did not exceed 17% at any time. B, The cells were treated with iPLA2 sense 
oligonucleotide (gray bars), iPLA2 antisense oligonucleotide (black bars) or neither 
(open bars) as described under Experimental Procedures. Afterwards the cells were 
incubated without (Control) or with 500 H2O2 for 20 h, and the number of apoptotic 
cells was determined by cytometry after staining with annexin V-FITC. Inset shows 
the iPLA2 protein content of control (C), sense-treated (S) or antisense-treated (A) 
cells, as measured by immunoblot. 
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